FDMT
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) has 5 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 14, 2026.
The most active filer is See Remarks Kirn David with 4 filings. Insiders have net sold $2.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:David H. Kirn
- Employees:196
- HQ:EmeryVille, CA, US
- IPO:2020-12-11
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.2M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$748.0M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| See Remarks | Sale | 42,608 | $548K | Jul 14 | SEC ↗ | |
| See Remarks | Sale | 15,725 | $189K | Jul 14 | SEC ↗ | |
| Chief Legal Officer | Sale | 6,566 | $92K | Jul 2 | SEC ↗ | |
Bizily ScottFirst filing | Chief Legal Officer | Sale | 9,810 | $118K | Jun 25 | SEC ↗ |
| See Remarks | Sale | 114,746 | $1.2M | Jun 23 | SEC ↗ | |
Kirn DavidFirst filing | See Remarks | Sale | 1,922 | $19K | Jun 2 | SEC ↗ |
Related companies
4D Molecular Therapeutics, Inc. is in the Healthcare sector.